stars 1 stars 2 stars 3

AccelBio is a pharmaceutical contract research organization (CRO) and diagnostic testing development and point-of-care services company. We provide actionable results for biotechnology programs and pharmaceutical research and discovery with a focus on customized RNA and neurobiology research, as well as immuno-oncology studies. Both non-GLP and GLP studies available. With our expertise in molecular cell biology and animal work, we leverage premier bioassays in multiple formats, including high-throughput screens using chemically unique entities for drug discovery. During COVID19 we applied our RNA expertise to develop novel, rapid high-throughput Viral RNA diagnostic platforms for SARS-CoV-2 detection globally. Our contract services enable the highest quality R&D focused on genetic models and disease pathways. White-glove diagnostic and other pathogen screening services. We contract under CLIA/CLEP and perform high-complexity diagnostic testing.

AccelBio Questions

The AccelBio annual revenue was $4 million in 2026.

Jason Dictenberg is the Chief Executive Officer and Chairman of AccelBio.

4 people are employed at AccelBio.

AccelBio is based in Farmingdale, New York.

The NAICS codes for AccelBio are [54171, 541714, 541, 54, 5417].

The SIC codes for AccelBio are [87, 873].

Top AccelBio Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users